Next Article in Journal
Liposomal Formulations Enhance the Anti-Inflammatory Effect of Eicosapentaenoic Acid in HL60 Cells
Next Article in Special Issue
The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies
Previous Article in Journal
Prodrug Therapies for Infectious and Neurodegenerative Diseases
Previous Article in Special Issue
Nanomicelle-Microsphere Composite as a Drug Carrier to Improve Lung-Targeting Specificity for Lung Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model

1
Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
2
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, India
3
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
4
Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail 81442, Saudi Arabia
5
Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
6
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
7
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia
8
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41552, Egypt
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(3), 519; https://doi.org/10.3390/pharmaceutics14030519
Submission received: 3 February 2022 / Revised: 20 February 2022 / Accepted: 22 February 2022 / Published: 26 February 2022

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder with synovitis and articular pathology as its primary expositions. Leflunomide (Lfd) is an anti-rheumatic drug that is effective in the treatment of RA, but displays severe side effects upon prolonged systemic administration. Local therapy might represent a promising strategy to treat rheumatoid arthritis without eliciting systemic adverse effects. In this study, leflunomide-loaded poly(ε-caprolactone) nanoparticles (Lfd-NPs) were prepared and assessed as a local drug delivery system capable of alleviating RA-associated inflammation. Lfd-NPs were optimized using the Quality by Design (QbD) approach, applying a 32 full factorial design. In vitro drug release from NPs was examined in simulated synovial fluid. In addition, the in vivo efficacy of Lfd-NPs was evaluated in the Adjuvant Induced Arthritis (AIA) rodent model. Sustained drug release in simulated synovial fluid was observed for up to 168 h. A gradual reduction in paw volume and knee diameter was observed over the course of treatment, indicating the regression of the disease. In addition, significant reductions in serum proinflammatory markers and cytokines, including the C-reactive protein (CRP), rheumatoid factor (RF), TNF-α, IL1-β, and IL-6, were verified upon treatment with Lfd-NPs, suggesting the modulation of immune responses at the pathological site. Most importantly, no remarkable signs of toxicity were observed in Lfd-NP-treated animals. Collectively, intra-articularly administered Lfd-NPs might represent a potential therapeutic alternative to systemically administered drugs for the treatment of rheumatoid arthritis, without eliciting systemic adverse effects.
Keywords: drug delivery; nanotherapeutics; rheumatoid arthritis; leflunomide; polymeric nanoparticle; poly-ε-caprolactone; adjuvant induced arthritis; intra-articular drug delivery drug delivery; nanotherapeutics; rheumatoid arthritis; leflunomide; polymeric nanoparticle; poly-ε-caprolactone; adjuvant induced arthritis; intra-articular drug delivery
Graphical Abstract

Share and Cite

MDPI and ACS Style

Singh, E.; Osmani, R.A.M.; Banerjee, R.; Abu Lila, A.S.; Moin, A.; Almansour, K.; Arab, H.H.; Alotaibi, H.F.; Khafagy, E.-S. Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model. Pharmaceutics 2022, 14, 519. https://doi.org/10.3390/pharmaceutics14030519

AMA Style

Singh E, Osmani RAM, Banerjee R, Abu Lila AS, Moin A, Almansour K, Arab HH, Alotaibi HF, Khafagy E-S. Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model. Pharmaceutics. 2022; 14(3):519. https://doi.org/10.3390/pharmaceutics14030519

Chicago/Turabian Style

Singh, Ekta, Riyaz Ali M. Osmani, Rinti Banerjee, Amr Selim Abu Lila, Afrasim Moin, Khaled Almansour, Hany H. Arab, Hadil Faris Alotaibi, and El-Sayed Khafagy. 2022. "Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model" Pharmaceutics 14, no. 3: 519. https://doi.org/10.3390/pharmaceutics14030519

APA Style

Singh, E., Osmani, R. A. M., Banerjee, R., Abu Lila, A. S., Moin, A., Almansour, K., Arab, H. H., Alotaibi, H. F., & Khafagy, E.-S. (2022). Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model. Pharmaceutics, 14(3), 519. https://doi.org/10.3390/pharmaceutics14030519

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop